Mirum raises 2026 net product sales outlook to $660M-$680M as it targets year-end zilurgisertib launch
Mirum Pharmaceuticals, Inc. Common Stock · PHARMACEUTICAL PREPARATIONS · Now $96.33
-7.2% in 7d after detection
Post-detection moves
1h
—
1d
+4.1%
3d
+3.8%
7d
-7.2%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS